Literature DB >> 1819715

Role for platelet-activating factor in asthma.

K F Chung1, P J Barnes.   

Abstract

Recent studies of the effects of platelet-activating factor (PAF) on human and animal airways would support a putative role for this lipid mediator in asthma. PAF can induce many aspects of the clinical and pathological features seen in asthmatic airways such as airway oedema, eosinophil accumulation in the airway wall, and bronchial hyperresponsiveness. PAF has potent activity as a chemotactic agent and as an activator of eosinophils, which are prominent cells in asthmatic airways, through the activation of specific surface receptors. The interaction between PAF and eosinophils may be crucial in the pathogenesis of bronchial hyperresponsiveness in asthma. A role for PAF in asthma can now be studied using the recently developed antagonists of the PAF receptor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1819715     DOI: 10.1007/BF02536547

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  28 in total

1.  Density heterogeneity of eosinophil leucocytes: induction of hypodense eosinophils by platelet-activating factor.

Authors:  T Yukawa; C Kroegel; P Evans; T Fukuda; K F Chung; P J Barnes
Journal:  Immunology       Date:  1989-09       Impact factor: 7.397

2.  The effect of the selective PAF antagonist BN 52021 on PAF- and antigen-induced bronchial hyper-reactivity and eosinophil accumulation.

Authors:  A J Coyle; S C Urwin; C P Page; C Touvay; B Villain; P Braquet
Journal:  Eur J Pharmacol       Date:  1988-03-22       Impact factor: 4.432

Review 3.  PAF antagonists. Their potential therapeutic role in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Drugs       Date:  1988-02       Impact factor: 9.546

4.  Effects of inhaled PAF in humans on circulating and bronchoalveolar lavage fluid neutrophils. Relationship to bronchoconstriction and changes in airway responsiveness.

Authors:  A J Wardlaw; K F Chung; R Moqbel; A J MacDonald; A Hartnell; M McCusker; J V Collins; P J Barnes; A B Kay
Journal:  Am Rev Respir Dis       Date:  1990-02

5.  Effect of platelet-activating factor on airway vascular permeability: possible mechanisms.

Authors:  T W Evans; K F Chung; D F Rogers; P J Barnes
Journal:  J Appl Physiol (1985)       Date:  1987-08

6.  Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils.

Authors:  A J Wardlaw; R Moqbel; O Cromwell; A B Kay
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

7.  Increased numbers of hypodense eosinophils in the blood of patients with bronchial asthma.

Authors:  T Fukuda; S L Dunnette; C E Reed; S J Ackerman; M S Peters; G J Gleich
Journal:  Am Rev Respir Dis       Date:  1985-11

8.  Phospholipid analysis of human eosinophils: high levels of alkylacylglycerophosphocholine (PAF precursor).

Authors:  A Ojima-Uchiyama; Y Masuzawa; T Sugiura; K Waku; H Saito; Y Yui; H Tomioka
Journal:  Lipids       Date:  1988-08       Impact factor: 1.880

9.  Ketotifen inhibits the cutaneous but not the airway responses to platelet-activating factor in man.

Authors:  K F Chung; P Minette; M McCusker; P J Barnes
Journal:  J Allergy Clin Immunol       Date:  1988-06       Impact factor: 10.793

10.  Damage of the airway epithelium and bronchial reactivity in patients with asthma.

Authors:  L A Laitinen; M Heino; A Laitinen; T Kava; T Haahtela
Journal:  Am Rev Respir Dis       Date:  1985-04
View more
  4 in total

1.  The localization of phospholipase A2 in the secretory granule.

Authors:  S P Chock; E A Schmauder-Chock; E Cordella-Miele; L Miele; A B Mukherjee
Journal:  Biochem J       Date:  1994-06-15       Impact factor: 3.857

Review 2.  Platelets in patients with aspirin-exacerbated respiratory disease.

Authors:  Tanya M Laidlaw; Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2015-06       Impact factor: 10.793

3.  Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor.

Authors:  S Ishii; T Nagase; F Tashiro; K Ikuta; S Sato; I Waga; K Kume; J Miyazaki; T Shimizu
Journal:  EMBO J       Date:  1997-01-02       Impact factor: 11.598

4.  Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study.

Authors:  Bastsetseg Ulambayar; Eun-Mi Yang; Hyun-Young Cha; Yoo-Seob Shin; Hae-Sim Park; Young-Min Ye
Journal:  Clin Transl Allergy       Date:  2019-07-17       Impact factor: 5.871

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.